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ORIGINAL ARTICLE
Background/Aims: The aim of our study was to determine the incidence and clinical features of severe
pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone
(CHOP) or rituximab plus CHOP (R-CHOP) as the initial treatment for lymphoma.
Methods: A retrospective analysis of pulmonary infection and drug-induced interstitial pneumonitis (DIIP) was
performed using lymphoma registry data. R-CHOP was administered in 71 patients and CHOP in 29 patients. 
Results: The severe pulmonary adverse events tended to occur more frequently with R-CHOP (18.3%) than
CHOP alone (13.8%), although the difference was not significant (p = 0.771). DIIP occurred in five patients in the
R-CHOP arm (7%) and in one in the CHOP arm (3%). The continuous use of steroids for conditions other than
lymphoma significantly increased the risk of pulmonary infection including Pneumocystis jiroveci pneumonia (p =
0.036) in the multivariate analysis. International prognostic index, tumor stage, smoking, previous tuberculosis,
chronic obstructive pulmonary disease, and lymphoma involvement of lung parenchyma were not related to
pulmonary adverse events. Patients who experienced severe pulmonary events showed shorter survival when
compared to those without complications (p = 0.002). 
Conclusions: Our experiences with serial cases with DIIP during chemotherapy and the correlation of continuous
steroid use with pulmonary infection suggest that the incidence of pulmonary complications might be high during
lymphoma treatment, and careful monitoring should be performed. (Korean J Intern Med 2010;25:86-92)
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INTRODUCTION
Rituximab is a chimeric monoclonal antibody that was
approved for the treatment of low-grade or follicular,
relapsed, or refractory lymphoma and CD20 positive B-
cell non-Hodgkin’s lymphoma (NHL). It is now
considered as a part of the standard therapy for CD20
positive B-cell NHL, especially for diffuse large B-cell
lymphoma [1]. Over 540,000 patients worldwide have
now received rituximab and serious adverse reactions
have occurred only in a minority of patients; in the vast
majority, rituximab is safe and well tolerated [2]. The
most common adverse events were infusion-related
and included fever, chills, and rigors. Respiratory
complications could include cough, rhinitis, brochospasm,
dyspnea, and sinusitis [3]. Severe pulmonary complications
such as cryptogenic organizing pneumonia and drug-
induced interstitial pneumonitis (DIIP) are very rare, with
most of our knowledge coming from case reports [4-6]. 
However, we have experienced cases of rituximab-
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associated pulmonary adverse events very frequently.
Therefore, this study analyzed these adverse events and the
clinical features of patients treated with cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) or
rituximab plus CHOP (R-CHOP). 
METHODS
Eligibility of patients
We retrospectively reviewed patients with NHL diagnosed
between September 2003 and April 2007. Eligible
patients were treated with R-CHOP or CHOP as the first
induction therapy for lymphoma at Seoul National
University Bundang Hospital. Patients with acquired
immunodeficiency syndrome- or central nervous system-
associated lymphoma were excluded. 
Treatment
Patients treated with CHOP received the combination of
cyclophosphamide (750 mg/m2, day 1), doxorubicin (50
mg/m2, day 1), vincristine (1.4 mg/m2, up to a maximal
dose of 2 mg, day 1), and prednisone (40 mg/m2/day, days
1 to 5). They were treated every 3 weeks. Patients treated
with R-CHOP received rituximab (375 mg/m2) on day 1 of
each cycle of CHOP according to standard prescribing
Table 1. Baseline characteristics of patients treated with CHOP or R-CHOP
Variables CHOP R-CHOP p value
(n = 29) (n = 71)
Age, yr 61.7 (19.7 - 80.7) 61.4 (21 - 83.8) NS
Sex NS
Male 17 (56.6) 38 (53.5)
Female 12 (41.4) 33 (45.5)
Histology according to WHO 0.000
B cell 5 (17.3) 71 (100)
T cell 24 (82.7) 0 (0)
Age-adjusted IPI NS
Low 9 (31.0) 23 (32.4)
Low-intermediate 9 (31.0) 16 (22.5)
High-intermediate 7 (24.1) 22 (31.0)
High 4 (13.8) 10 (14.1)
Performance status NS
0 - 1 19 (65.5) 58 (81.7)
2 - 4 10 (34.5) 13 (18.3)
Stage NS
I 7 (24.1) 5 (7.0)
II 12 (41.4) 30 (42.3)
III 5 (17.2) 11 (15.5)
IV 5 (17.2) 25 (35.2)
Steroid long term use NS
Yes 2 (6.9) 4 (5.6)
No 27 (93.1) 67 (94.4)
Lung parenchymal involvement 4 (13.8) 5 (7.0) NS
Bone marrow involvement 1 (3.4) 11 (15.5) NS
Smoking 8 (27.6) 14 (19.2) NS
History of pulmonary tuberculosis 2 (6.9) 7 (9.9) NS
Chronic obstructive pulmoanry disease 2 (6.9) 3 (4.2) NS
Chemotherapy cycles 5 (1- 6) 5 (1 - 8) NS
Values are presented as median (range) or number (%) unless otherwise indicated.
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP, rituximab plus CHOP; NS, not significant; WHO, World
Health Organization; IPI, international prognostic index.
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guidelines, following the administration of oral aceta-
minophen (650 mg) and intravenous pheniramine (45.5
mg). An additional two cycles of CHOP or RCHOP were
given after achievement of complete remission. 
Assessment of pulmonary adverse events
An adverse event was defined as any adverse change
from the patient’s baseline condition. Each event was
graded according to the National Cancer Institute Common
Toxicity Criteria grading system. The definition of severe
pulmonary complications was all adverse events of grade
3 or more that occurred in the lungs, such as infection and
DIIP, after chemotherapy was completed. The diagnosis
of pulmonary complications, especially DIIP, was made
mainly by radiological findings and laboratory or
pathological methods along with clinicians’ experience.
Diagnostic criteria were as follows. The radiological
method consisted mainly of high-resolution computed
tomography (HRCT). HRCT findings in DIIP showed a
diffuse interstitial pattern, such as ground-glass opacity,
alveolitis, and diffuse infiltrates. The predominant
abnormalities on pulmonary function tests were a
restrictive pattern and a reduction in the diffusing capacity
of the lung for carbon monoxide (DLCO). Pathological
results were consistent with interstitial fibrosis. Clinical
aspects included symptoms, no evidence of infectious
etiology, association with drug administration, and good
response to immunosuppressants such as corticosteroids.
Statistical methods
All continuous variables were analyzed using the Mann-
Whitney U test. Proportions were compared using the χ2
test or logistic regression analysis. Overall survival was
estimated with the Kaplan-Meier method and was
compared using the log-rank test. Statistical analysis was
performed with SPSS version 10.0 (SPSS Inc., Chicago, IL,
USA) and significance levels were two-sided at p < 0.05.
RESULTS
Patient characteristics
The subjects consisted of 100 patients: 71 treated with
R-CHOP and 29 with CHOP as an initial regimen, all of
whom received at least one cycle of chemotherapy. The
median age of the patients was 61 years (range, 19 to 83).
No significant difference existed in any clinical characteristics
between the two groups, except for histology (Table 1).
Most patients treated with CHOP had NHL of T-cell
Table 2. Histologic subtypes of non-Hodgkin’s
lymphoma by chemotherapy regimens
Histolgy CHOP R-CHOP
(n = 29) (n = 71)
Diffuse large B cell lymphoma 10 65
Anaplastic large cell lymphoma 6 0
Extranodal NK/T cell lymphoma 2 0
Angioimmunoblastic T cell lymphoma 3 0
Blastic NK cell lymphoma 1 0
Extranodal marginal zone B cell lymphoma 1 0
Peripheral T cell lymphoma 3 0
Small lymphocytic lymphoma 1 0
T cell lymphoblastic lymphoma 1 0
Nasal NK/T cell lymphoma 1 0
Follicular lymphoma 0 3
B cell lymphoma 0 1
Mantle cell lymphoma 0 1
Mature B cell lymphoma 0 1
CHOP, cyclophosphamide, doxorubicin, vincristine, and
prednisone; R-CHOP, rituximab plus CHOP. 
Table 3. Pulmonary complications in patients treated with  CHOP or R-CHOP
Pulmonary complications CHOP R-CHOP p value
(n = 29) (n = 71)
Pneumocystis jirovecii pneumonia 4a 2 NS
Drug-induced interstitial pneumonitis 1 5 NS
Bacterial pneumonia with neutroepnia 0 5 NS
Tuberculosis 0 1 NS
Total (%) 4b (13.8) 13 (18.3) NS
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP, rituximab plus CHOP; NS, not significant.
a Drug-induced interstitial pneumonitis led to prolonged steroid usage, which resulted in Pneumocystis jirovecii pneumonia with positive
direct fluorescent monoclonal antibody assay later. 
b One patient suffered from both drug-induced interstitial pneumonitis and Pneumocystis jirovecii pneumonia. 
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lineage (82.7%), while all patients treated with R-CHOP
had NHL of B-cell lineage (Table 2). None received
Pneumocystis jirovecii pneumonia (PJP) prophylaxis or
prophylactic antibiotics during chemotherapy. 
Clinical features of pulmonary adverse events
Pulmonary complications in patients receiving treatment
with CHOP or R-CHOP are listed in Table 3. Pulmonary
complications were seen in 13 cases (18.3%) in the R-
CHOP group and four (13.8%) in the CHOP group. Median
age in the CHOP and R-CHOP group was 61.7 and 61.4
years, respectively. The most frequent pulmonary
complications in the R-CHOP group were DIIP (7.0%, n =
5) and bacterial pneumonia associated with neutropenic
fever (6.8%, n = 5). The former was diagnosed by
pathological confirmation (n = 1) or combination of HRCT
and consultation with a pulmonologist (n = 4). Clinical
features of patients with rituximab-induced interstitial
pneumonitis (RIIP) are summarized in Table 4. PJP
(2.8%, n = 2) was diagnosed by positive direct fluorescent-
antibody (DFA) assay from bronchoalveolar lavage. One
patient without a previous history of pulmonary
tuberculosis (TB) developed TB after three cycles of R-
CHOP. The median time from the start of R-CHOP to
DIIP was 2.9 months (range, 0.9 to 3.9). 
Four patients treated with CHOP developed PJP, three
of whom were negative with DFA. However, we diagnosed
three patients with PJP after considering all the factors,
such as exclusion of bacterial or fungal pneumonia, CT
imaging, and improvement after administration of
trimethoprim-sulfamethoxazole. In one patient who was
positive by DFA, PJP appeared secondary to prolonged
steroid use after he was diagnosed with DIIP. 
Figure 1. Comparison of survival between patients with or
without pulmonary adverse events.
Table 4. Clinical features of patients with rituximab-induced interstitial pneumonitis
Age, Sex Subtype Cycle, Time from Presenting CT finding DLCO Pathology Treatment Outcome
yr of lymphoma n rituximab symptom
administration
to DIIP, day
Case 1 65 Male DLBL 6 14 Fever Ground-glass NA DIIP Prednisone Improved
opacity;
Interstitial thickening
Case 2 64 Male DLBL 1 29 Dry cough Ground-glass NA NA Prednisone Expired
opacity;
Fibrotic and reticular 
density
Case 3 71 Male DLBL 6 27 Dyspnea Ground-glass NA DIIP Prednisone Improved
opacity;
Interstitial thickening
Case 4 54 Male DLBL 8 29 Dyspnea Diffuse interstitial  Decrease DIIP Prednisone Improved
thickening
Case 5 86 Female DLBL 3 22 Dyspnea Diffuse ground-glass NA NA Prednisone Improved
opacity
CT, computed tomography; DLCO, diffusing capacity of the lung for carbon monoxide; DLBL, diffuse large B-cell lymphoma; DIIP,
drug-induced interstitial pneumonitis; NA, not available.
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Clinical variables related to pulmonary 
complications
Initial chemotherapy regimens such as CHOP and R-
CHOP did not differ significantly for incidence of
pulmonary adverse events (p = 0.771). The patients’
characteristics were compared according to the pulmonary
complications, irrespective of chemotherapy regimen
(Table 5). For univariate analysis, higher age-adjusted
international prognostic index (IPI), higher stage, and
longer steroid usage were related to occurrence of
pulmonary complications. Performance status, smoking,
previous TB, comorbidity with chronic obstructive
pulmonary disease, and lung parenchymal involvement
by lymphoma were not related to pulmonary adverse
events. In the multivariate analysis, only the prolonged
use of steroids significantly increased the risk of PJP and
pulmonary infection (p = 0.036).
Patients with pulmonary toxicity showed significantly
lower overall survival than those without complications (p
= 0.002, Fig. 1). Eight of 17 patients with pulmonary
complications died. The causes of death were as follows:
two with DIIP, one with PJP, one with pneumonia, and
four from disease progression. 
DISCUSSION
Rituximab is a human/mouse chimeric monoclonal
antibody (IgG1) that reacts specifically with the CD20
antigen that is expressed on > 95% of normal and
Table 5. Patient characteristics according to pulmonary adverse events
Variables Pulmonary complications No pulmonary complications p value
(n = 17) (n = 83)
Age, yr 62 (46 - 84) 59 (20 - 79) NS
Sex
Male 11 (64.7) 44 (53.0) NS
Female 6 (35.3) 39 (47.0)
Age-adjusted IPIa
Low 1 (5.9) 31 (37.3)
Low-intermediate 4 (23.5) 21 (25.3 0.007
High-intermediate 8 (47.1) 21 (25.3)
High 4 (23.5) 10 (12.0)
Performance status
0 - 1 13 (76.5) 64 (77.1) NS
2 - 4 4 (23.5) 19 (22.9)
Stage
I 0 (0) 12 (14.5)
II 4 (23.5) 38 (45.8) 0.012
III 6 (35.3) 10 (12.0)
IV 7 (41.2) 23 (27.7)
Steroid long term use
Yes 4 (23.5) 2 (2.4) 0.007
No 13 (76.5) 81 (97.6)
Lung parenchymal involvement 2 (11.8) 7 (8.4) NS
Bone marrow involvement 3 (17.6) 9 (10.8) NS
Smoking 5 (29.4) 17 (20.5) NS
History of pulmonary tuberculosis 1 (5.9) 8 (9.6) NS
Chronic obstructive pulmoanry disease 2 (7.4) 3 (3.6) NS
Chemotherapy cycles 5 (1 - 7) 6 (1 - 8) NS
Values are presented as median (range) or number (%) unless otherwise indicated.
NS, not significant; IPI, international prognostic index.
aAge > 60, serum lactate dehydrogenase concentration greater than normal, Eastern Cooperative Oncology Group (ECOG) performance
status ≥ 2, Ann Arbor clinical stage III or IV, number of involved extranodal disease sites > 1. 
Lim KH, et al. Pulmonary adverse effects of R-CHOP    91
malignant B cells, and induces complement-mediated and
antibody-dependent cellular cytotoxicity. In patients with
relapsed, low-grade NHL, peripheral blood B-cell depletion
occurs within 24 to 48 hours after the first infusion of
rituximab. Recovery of B cells begins 6 to 9 months after
completion of therapy, and normal levels are obtained
after 9 to 12 months [7]. The prolonged period of rituximab-
induced B-cell depletion might compromise the immune
system. However, the Groupe d’Etude des Lymphomes de
l’Adulte (GELA) group compared R-CHOP with CHOP
alone in elderly patients with aggressive NHL, and found
no major difference between the two arms in terms of
toxicity or severe infection, with a significantly superior
survival in the R-CHOP group [1]. Recently, rituximab has
been used as a first-line agent in combination with CHOP
for the treatment of CD20 positive B-cell NHL. 
Although the use of rituximab has increased, the rate of
possible drug-induced lung injury is currently < 0.03% in
more than 540,000 patients treated worldwide [2].
However, we have observed post-chemotherapy pulmonary
toxicity more frequently. Although R-CHOP did not
induce significantly more pulmonary complications than
CHOP, our study showed that rituximab-containing
therapy tended to cause DIIP and bacterial pneumonia
more frequently. The former probably was related to
rituximab, which was previously reported to have a low
incidence [8-13]. 
According to one report of 16 patients with RIIP, the
average number of cycles of rituximab prior to presentation
of RIIP was four, and the most common symptoms at
presentation included dyspnea (81%), fever (72%), and
cough (36%) [11]. Evaluations should include pulse
oximetry or blood gas analysis, HRCT of the chest to seek
out diffuse interstitial infiltrates, and pulmonary function
tests to look for a restrictive pattern and decreased DLCO.
Bronchoscopy with bronchoalveolar lavage should be
performed to rule out an infectious etiology, and biopsy
can demonstrate alveolar damage and interstitial fibrosis.
The pathogenesis of RIIP is largely unknown. A
potential explanation for RIIP may be the induction and
release of cytotoxic substances. Rituximab acts by binding
to CD20 positive B cells. Toxicity and efficacy are related
to events after binding, which include B-cell signaling,
complement activation, direct apoptosis, and antibody-
dependent cellular cytotoxicity [14]. Complement
activation and cytokine secretion seem to be causative
factors of the side effects associated with infusion
reactions [15]. In particular, tumor necrosis factor (TNF)-
α has been postulated as the main component in the
pathogenesis of RIIP because of its proinflammatory
effects by inducing chemokines, inflammatory mediators,
and angiogenic factors [16]. Therapy of RIIP must include
immediate discontinuation of rituximab and high-
dose corticosteroids, and any other clinically necessary
supportive therapy such as anti-TNF-α therapy might be
attempted in patients whose clinical condition worsens
despite corticosteroids [11]. The duration of steroid
therapy is usually 1 to 2 months. Patients who worsen
despite corticosteroids can have a fatal outcome [17].
Several factors could account for the higher incidence
of DIIP in our study than that reported previously. The
first factor was the failure to recognize this complication
by attributing the DIIP symptoms to infection or the
underlying disease in previous studies. The second was
the distribution to higher age-adjusted IPI and stage in the
R-CHOP group, which was attributed to more frequent
pulmonary complications, by univariate analysis. When
used in combination with a variety of chemotherapeutic
regimens, rituximab is known to cause a higher rate of
neutropenia, which does not translate into a higher
infection rate [18,19]. However, the frequent neutropenia
caused by R-CHOP may increase the probability of
infection and lead to higher incidence of bacterial
pneumonia than with CHOP alone. Reactivation of
pulmonary TB was probably associated with impairment
of cellular immunity induced by rituximab and steroids,
even if in our one case.
Overall survival was analyzed according to whether
patients had pulmonary complications. Overall survival in
patients with severe pulmonary toxicity was shorter than
that in patients without, which caused death by pulmonary
complications themselves and disease progression after an
inevitable discontinuation of treatment.
In conclusion, the incidence of rituximab-related
pulmonary complications may be higher than has been
reported previously [2]. These adverse events, especially
DIIP, lead to prolonged use of corticosteroids, which
may increase the risk of infection such as PJP and TB.
Rituximab-induced pulmonary toxicity should be
recognized early and treated effectively because of its
associated high mortality and morbidity. Also, a prolonged
use of corticosteroids for conditions other than lymphoma
requires caution. 
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